Conditionally MYC:insights from novel transgenic models

Constadina Arvanitis, Dean W. Felsher*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


MYC was one of the first oncogenes identified to be associated with chromosomal aberrations and one of the most common oncogenes involved in the pathogenesis of cancer. However, until recently it was not clear if MYC would be a good target for the treatment of cancer. New conditional transgenic models have been used to demonstrate that even the brief inactivation of MYC can reverse tumorigenesis. Here we review results from recent experimental model systems, which demonstrate that the inactivation of MYC may be a specific and effective treatment for many types of cancer.

Original languageEnglish (US)
Pages (from-to)95-99
Number of pages5
JournalCancer Letters
Issue number2
StatePublished - Aug 26 2005

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Conditionally MYC:insights from novel transgenic models'. Together they form a unique fingerprint.

Cite this